Zidovudine

Zidovudine is an antiretroviral NRTI used in Intro to Pharmacology to show how HIV drugs block reverse transcriptase and lower viral replication.

What is zidovudine?

Zidovudine is an antiretroviral drug in Intro to Pharmacology that works as a nucleoside reverse transcriptase inhibitor, or NRTI. It is one of the classic HIV medications because it targets a step the virus needs to copy itself inside a host cell.

The basic idea is simple: HIV carries its genetic material as RNA, but to keep infecting cells, it has to turn that RNA into DNA. Zidovudine interferes with reverse transcriptase, the viral enzyme that does that conversion. Because the virus cannot make usable DNA as efficiently, replication slows down and the viral load can drop.

Pharmacology classes usually connect zidovudine to the larger concept of nucleoside analogs. A nucleoside analog looks enough like a normal building block of DNA that the virus tries to use it, but the drug disrupts the process. That makes zidovudine a good example of selective toxicity, where a drug targets a viral process more than the host cell’s own machinery.

You will also see zidovudine discussed as part of antiretroviral therapy, not usually as a stand-alone drug. HIV mutates quickly, so using a single drug makes resistance more likely. Combining zidovudine with other antiretroviral agents gives better control of the infection and lowers the chance that the virus can escape treatment.

A useful detail for class is that zidovudine has a real safety tradeoff. One of its best-known adverse effects is bone marrow suppression, which can lead to anemia and neutropenia. That means the drug can reduce a patient’s ability to carry oxygen and fight infection, so it is not just about stopping the virus, it is also about monitoring the patient’s blood counts.

You may also see zidovudine in post-exposure prophylaxis, or PEP, after possible HIV exposure. That is a good example of how pharmacology links mechanism to timing: the drug works best when it is started quickly enough to interrupt early viral replication before infection becomes established.

Why zidovudine matters in Intro to Pharmacology

Zidovudine matters because it connects several core Intro to Pharmacology ideas in one drug: viral enzyme inhibition, nucleoside analog structure, combination therapy, adverse effects, and resistance. If you can explain zidovudine, you can usually explain the logic behind a whole class of antiviral drugs.

It also gives you a clean way to trace cause and effect. The drug blocks reverse transcriptase, which reduces viral DNA synthesis, which lowers viral replication, which can reduce viral load and slow disease progression. That chain is exactly the kind of mechanism you are expected to describe when a class asks you to connect drug action with clinical outcome.

Zidovudine also shows why pharmacology is never just about the target. The same drug that helps control HIV can suppress bone marrow, so you have to think about therapeutic benefit and toxicity together. That balance shows up all over the course, especially when you compare antiviral drugs by mechanism, side effects, and resistance patterns.

Because it is an older, historically important HIV drug, zidovudine also helps anchor newer topics. Once you understand it, it is easier to compare older NRTIs with other antiretrovirals such as protease inhibitors or integrase inhibitors, and to see why combination regimens became the standard approach.

How zidovudine connects across the course

Reverse transcriptase

Zidovudine works by inhibiting reverse transcriptase, the HIV enzyme that converts viral RNA into DNA. If you understand this enzyme, zidovudine stops being a memorized drug name and becomes a specific mechanism. On quizzes, the key move is linking the drug to the enzyme it blocks and the replication step it disrupts.

NRTI

Zidovudine is a nucleoside reverse transcriptase inhibitor, so it belongs to the NRTI class. That class label tells you a lot more than the name alone, including that it mimics nucleosides and interferes with viral DNA synthesis. When comparing antivirals, class membership helps you predict both mechanism and common adverse effects.

Antiretroviral therapy

Zidovudine is usually studied as part of combination antiretroviral therapy rather than as a solo medication. This connection matters because HIV treatment uses multiple drugs to attack different steps in the viral life cycle and reduce resistance. If a case asks why one drug is not enough, combination therapy is the answer.

Lipodystrophy

Lipodystrophy is one of the longer-term side effects that can come up in antiretroviral treatment discussions. It is not the same as the bone marrow suppression caused by zidovudine, but it belongs in the same conversation about drug toxicity and patient monitoring. In class, this helps you separate side effects by drug class and by body system.

Is zidovudine on the Intro to Pharmacology exam?

A quiz question might ask you to match zidovudine with its drug class, mechanism, or major toxicity. The fastest path is to identify it as an NRTI that inhibits reverse transcriptase, then connect that to reduced HIV replication. If the question uses a patient scenario, look for clues about HIV treatment, post-exposure prophylaxis, or blood count problems such as anemia or neutropenia.

In short-answer or case-analysis questions, you may need to explain why zidovudine is given with other antiretrovirals instead of alone. That is where you mention resistance and combination therapy. If the prompt asks about safety monitoring, connect the drug to bone marrow suppression and explain why labs matter after treatment starts.

Zidovudine vs Protease Inhibitors

Zidovudine is an NRTI, so it blocks reverse transcriptase early in HIV replication. Protease inhibitors act later, stopping viral protein processing and maturation. They are both antiretrovirals, but they do different jobs at different stages of the viral life cycle, which is why they are often used together in combination therapy.

Key things to remember about zidovudine

• Zidovudine is an NRTI antiretroviral used against HIV.

• It blocks reverse transcriptase, so HIV cannot efficiently make DNA from its RNA.

• It is usually given with other antiretroviral drugs to limit resistance and improve control of the virus.

• A major side effect is bone marrow suppression, which can cause anemia and neutropenia.

• It can also be used in post-exposure prophylaxis after a possible HIV exposure.

Frequently asked questions about zidovudine

What is zidovudine in Intro to Pharmacology?

Zidovudine is an antiretroviral NRTI used to treat HIV. In pharmacology, it is a classic example of a drug that blocks reverse transcriptase and interferes with viral DNA synthesis. You will usually see it discussed alongside other HIV drugs and their side effects.

How does zidovudine work?

Zidovudine inhibits reverse transcriptase, the enzyme HIV uses to convert RNA into DNA. By slowing that step, the drug reduces viral replication and helps lower viral load. That mechanism is why it is grouped with nucleoside analogs and NRTIs.

What are the side effects of zidovudine?

The most commonly tested adverse effects are bone marrow suppression, anemia, and neutropenia. Those side effects matter because they can leave a patient more vulnerable to fatigue or infection. In class, this is often paired with the idea of monitoring blood counts during treatment.

Is zidovudine the same as protease inhibitors?

No. Zidovudine is an NRTI that works early by blocking reverse transcriptase. Protease inhibitors work later in the HIV life cycle by preventing viral protein processing. They are both antiretroviral drugs, but they target different steps, which is why they are often combined.